Federated Hermes’s KalVista Pharmaceuticals KALV Stock Holding History

Federated Hermes’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$74.9K	Buy	3,719 +3,644	+4,859%	+$58.7K	﹤0.01%	1633
2025 Q4	$1.21K	Buy	+75	New	+$993	﹤0.01%	2008
2021 Q3	–	Sell	-39	Closed	-$1K	–	2274
2021 Q2	$1K	Hold	39	–	–	﹤0.01%	2136
2021 Q1	$1K	Buy	+39	New	+$1.02K	﹤0.01%	2172
2020 Q2	–	Sell	-266	Closed	-$2K	–	2307
2020 Q1	$2K	Buy	+266	New	+$3.59K	﹤0.01%	2019
2019 Q2	–	Sell	-491	Closed	-$14K	–	2187
2019 Q1	$14K	Buy	491 +205	+72%	+$4.44K	﹤0.01%	1821
2018 Q4	$6K	Buy	286 +138	+93%	+$2.77K	﹤0.01%	1950
2018 Q3	$3K	Buy	+148	New	+$2K	﹤0.01%	2112
2018 Q2	–	Sell	-503	Closed	-$5K	–	2241
2018 Q1	$5K	Buy	+503	New	+$5.27K	﹤0.01%	1964

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes's KALV Position: Q1 2026 in Review

Federated Hermes increased its KalVista Pharmaceuticals (KALV) stake by 4,859% in Q1 2026, buying an estimated $58.7K and bringing the position to 3,719 shares worth $74.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1633.

Federated Hermes first reported a position in KALV in Q1 2018 and has held it in 9 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Federated Hermes held 3,719 shares of KalVista Pharmaceuticals worth $74.9K as of Q1 2026.
Federated Hermes bought 3,644 KalVista Pharmaceuticals shares in Q1 2026, an estimated $58.7K.
KalVista Pharmaceuticals made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1633 holding.
Federated Hermes first reported a position in KalVista Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.